Recent Company News

• 08:04 AM ET Nov 12, 2025
  

  EU chemicals seen facing structural collapse despite bright spots in fertilizers and specialty names:

• 07:49 AM ET Nov 06, 2025
  

  Transcript Intelligence: Novonesis Q3 Earnings Guidance (DKK 413.70, +25.80)

• 04:50 AM ET Nov 06, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 04:02 AM ET Nov 06, 2025
  

  Transcript Intelligence: Novonesis Q3 Earnings Themes (DKK414.10, +26.20)

• 04:02 AM ET Nov 06, 2025
  

  Transcript Intelligence: Novonesis Q3 Earnings Q&A (DKK414.10, +26.20)

• 02:51 AM ET Nov 06, 2025
  

  StreetAccount Metrics Recap - Novonesis Q3 Earnings (DKK 387.90, 0.00)

• 02:03 AM ET Nov 06, 2025
  

  Novonesis reports Q3 Adjusted Net profit €192.1M vs FactSet €197.5M; now expects FY Organic sales growth between +7-8% vs prior guidance +6-8% (DKK 387.90, 0.00)

• 04:32 AM ET Nov 05, 2025
  

  StreetAccount Consensus Metrics Preview - Novonesis Q3 Earnings (DKK 386.80, +4.90)

• 03:02 AM ET Sep 29, 2025
  

  Savara presents new data from the phase 3 IMPALA-2 clinical trial of molgramostim in patients with autoimmune pulmonary alveolar Proteinosis (aPAP) at ERS 2025 ($3.52, 0.00)

• 02:48 AM ET Sep 08, 2025
  

  Novonesis and Novo Nordisk to explore new solutions to improve metabolic health (DKK 409.70, 0.00)